About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BMY - Bristol-Myers Squibb...| Previous Close | $66.02 | Open | $66.02 |
| Volume | 11.3M | Market Cap | 149.383B |
| Yield | 2.76 % | Last Dividend | $1.82 |
| Bristol Myers' top hematology exec is on... | 01/14/21 |
| Fourteen days after the $6.3 billion CVR tied to the approval of liso-cel went up in smoke, one of the top execs in charge of the work at Bristol Myer... | |
| Leading Biopharmaceutical Companies Sele... | 01/14/21 |
| SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new... | |
| NantKwest Reports Positive Interim Data ... | 01/14/21 |
| Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK ) reports positive interim data on survival rates in the Metastatic Pancreatic Cancer Q... | |
| Bristol Myers Looks to Its Drug Pipeline... | 01/12/21 |
| The drugmaker expects its current pipeline of drugs could generate $25 billion in annual revenue and sees opportunities for more acquisitions. | |
| Bristol-Myers Squibb announced a $2 bill... | 01/12/21 |
| Bristol-Myers Squibb announced a $2 billion share buyback program, sending shares of the biopharmaceutical company up 4% on Monday. Bristol-Myers??? (... | |
| Small Cell Lung Cancer Therapeutics Mark... | 01/12/21 |
| Market Research Intellect have recently published a new report on the global Small Cell Lung Cancer Therapeutics market. The study provides profound i... | |
| Bristol-Myers To Buy Back Another $2B In... | 01/12/21 |
| Bristol-Myers Squibb announced a $2 billion share buyback program, sending shares of the biopharmaceutical company up 4% on Monday. Bristol-Myers??? (... | |
| Illumina Announces New and Expanded Onco... | 01/11/21 |
| SAN DIEGO--(BUSINESS WIRE)--With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio... | |
| JPM: Deal-making still a 'top priority' ... | 01/11/21 |
| Even after shelling out $74 billion for Celgene and $13.1 billion for MyoKardia, Bristol Myers Squibb still has ???significant financial flexibility??... | |
| Covid-19 Impact On Cell and Gene Therapy... | 01/11/21 |
| COHERENT MARKET INSIGHTS has added a new report titled Global Cell and Gene Therapy Market with analysis provides the insights which bring marketplace... | |
| Covid-19 Impact On Oncology Drugs Market... | 01/11/21 |
| COHERENT MARKET INSIGHTS has added a new report titled Global Oncology Drugs Market with analysis provides the insights which bring marketplace clearl... | |
| GRAIL Announces Collaborations with Amge... | 01/11/21 |
| GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amge | |
| Bristol Myers Squibb ??? $2 B Incrementa... | 01/11/21 |
| Brings Total Outstanding Share Repurchase Authorization to Approximately $6.4 Billion NEW YORK (STL.News) Bristol Myers Squibb (NYSE: BMY) today annou... | |
| Bristol Myers Squibb Announces $2 Billio... | 01/11/21 |
| Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization | |
| Global Cell and Gene Therapy Market Repo... | 01/07/21 |
| DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMark... | |
| Bristol Myers Squibb ices licensing pact... | 01/07/21 |
| Back in late 2019, South San Francisco's ArsenalBio uncorked an $85 million round to kickstart its designer T cell project with some splashy backers o... | |
| ArsenalBio Announces Multi-Program Disco... | 01/07/21 |
| SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ArsenalBio announces multi-program discovery collaboration with Bristol Myers Squibb to advance next-gen... | |
| Patent Medicine Market With Leading Play... | 01/07/21 |
| An off-the-shelf report on Patent Medicine Market which has been compiled after an in-depth analysis of the market trends prevailing across five geogr... | |
| Pharma firms ring in 2021 by hiking pric... | 01/05/21 |
| Nothing says ???happy new year??? like pricier prescriptions. Drugmakers have already raised list prices on more than 500 drugs in the US in the first... | |
| Global Combination antibody therapy Mark... | 01/05/21 |
| Data Bridge Market Research has recently added a concise research on the Global Combination antibody therapy Market to depict valuable insights relate... | |
| Evotec Achieves Milestone in Its Neurode... | 01/05/21 |
| ADDING ANOTHER DRUG DISCOVERY PROJECT TO THE PORTFOLIO TRIGGERS PAYMENT TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / January 5, 2021 / Evotec SE (Frankfu... | |
| Drug-makers kick off 2021 with 500 US pr... | 01/04/21 |
| Drug-makers including Abbvie Inc and Bristol Myers Squibb raised US list prices on more than 500 drugs to kick off 2021, according to an analysis by h... | |
| Drugmakers kick off 2021 with 500 US pri... | 01/04/21 |
| Drugmakers including Abbvie Inc and Bristol Myers Squibb raised U.S. list prices on more than 500 drugs to kick off 2021, according to an analysis ??? | |
| U.S. considers giving half-doses of Mode... | 01/04/21 |
| Investors in a deal sweetener created when Bristol Myers Squibb acquired Celgene in 2019 have seen their all-or-nothing bet wiped out. | |
| European Medicines Agency Validates Bris... | 01/04/21 |
| PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates Bristol Myers Squibb???s Application for Opdivo (nivolumab) as Adj... | |
| European Medicines Agency Validates Bris... | 01/04/21 |
| PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates Bristol Myers Squibb???s Application for Opdivo (nivolumab) Combin... | |
| Oncology Drugs Market Major Giants Conti... | 01/04/21 |
| The latest 100+ page survey report on Oncology Drugs Market is released by CMI covering various players of the industry selected from global geographi... | |
| Bristol-Myers Derivative Is Now Worthles... | 01/01/21 |
| (Bloomberg) -- Investors in a deal sweetener created when Bristol-Myers Squibb Co. acquired Celgene Corp. in 2019 have seen their all-or-nothing bet w... | |
| Bristol Myers Squibb Provides Update on ... | 01/01/21 |
| PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Status of Contingent Value Rights | |
| Global Checkpoint Inhibitors Market Repo... | 12/30/20 |
| DUBLIN--(BUSINESS WIRE)--The "Checkpoint Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMark... | |
| Buy rating | 11/17/20 |
| Mizuho maintains Buy rating and lowers Price Target from $6.17 to $3.34 | |
| Buy rating | 11/16/20 |
| Societe Generale upgrades from Hold to Buy rating and announces Price Target of $76.00 | |
| Buy rating | 11/10/20 |
| and announces Price Target of $72.00 | |
| Hold rating | 10/23/20 |
| Truist Securities initiates coverage with Hold rating and announces Price Target of $65.00 | |
| Date | 2020-11-05 (BMO) | Est. (EPS/Rev.) | $1.49/ 10.33B |
| Actual (EPS/Rev.) | $1.63/ $10.54 B | EPS (TTM) | 0.81 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Options Eagle | George | 78.00 % | Follow |
| Option Superstars | James Catzen | 75.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| optionguy | Vipul Champaneri | 61.00 % | Follow |
| Options Marc | Marc M | 55.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
